AstraZeneca Plc’s Covid-19 vaccine demonstrated 74 percent efficacy at preventing symptomatic disease, a figure that increased to 83.5 percent in people aged 65 and older, according to long-awaited results of the company’s U.S. clinical trial published on Sept. 29
Laboratory studies show that Merck & Co.’s experimental oral Covid-19 antiviral drug molnupiravir is likely to be effective against known variants of the coronavirus, including the dominant, highly transmissible Delta, the company said on Sept. 29.
AbbVie Inc. said on Sept. 28 the U.S. health regulator approved the company’s once-daily oral medicine Qulipta for the preventive treatment of migraine in adults, adding a third product to the drugmaker’s arsenal of therapies for severe headaches.
In the 40 years since the HIV epidemic first came to light, treatment options for those infected have come a long way. During January 2021, the FDA approved ViiV Healthcare’s Cabenuva as the very first once-a-month injection for HIV patients. But the Research Triangle pharma is not satisfied yet.
As Merck & Co. and Pfizer Inc. prepare to report clinical trial results for experimental Covid-19 antiviral pills, rivals are lining up with what they hope will prove to be more potent and convenient oral treatments of their own.
French specialty vaccine company Valneva and U.S. drugmaker Pfizer reported positive results from the companies’ Phase II study on a vaccine candidate for Lyme disease.
GlaxoSmithKline said on Sept. 28 the company would develop an HIV treatment with Japan’s Shionogi for use in regimens with dosing gaps of three months or more, as the drugmaker seeks to build on the success of GSK’s previous long-acting therapies.
Sanofi is dropping plans for the company’s own mRNA-based Covid-19 vaccine because of the dominance achieved by BioNTech-Pfizer and Moderna in using the technology to fight the pandemic, the company said on Sept. 28.
Pfizer Inc. and BioNTech SE on Sept. 28 submitted initial trial data for their Covid-19 vaccine in 5-11 year olds and said they would make a formal request with U.S. regulators for emergency use in the coming weeks.
Less than a month after appointing a new chief executive officer, Ziopharm Oncology announced a restructure that resulted in more than 50 percent of the company’s workforce being axed.
